Define the non-negotiables
Product form, cannabinoid range and basis, treatment, age, microbiology, packaging and substitution tolerances.
For licensed European buyers
Source against the requirement, not the catalogue.
Provenance screens medical-cannabis supply against one defined buying need. We compare the product, current evidence, destination route, timing and economics before a controlled introduction is considered.
For licensed and otherwise authorized commercial operators. Not for patients or consumers. The initial screen is free and creates no purchase obligation.
The procurement problem
A supplier claim is not yet a usable option.
A buyer still needs to know whether the offered product is current, whether the documents relate to the relevant entity and lot, how the product would reach the required commercial stage, and whether prices are being compared on an equivalent basis.
Name the responsible parties
Destination, importer, manufacturing or conversion steps, testing and the party responsible for any required batch certification or release.
Separate a lot from a capability
Current lot ID, allocable quantity, availability date, evidence linkage, MOQ and quote validity—not historical production capacity alone.
Compare the same delivery stage
Currency, unit, Incoterm and named place, included processing, testing, freight and release costs, and all still-unpriced items.
What the first screen returns
One of three useful answers.
The purpose is a purchasing decision—not a long list of growers.
Worth controlled diligence
A small number of anonymous capabilities appear aligned, with the current evidence and gaps made visible.
A decision is premature
The exact missing field, evidence item or commercial term is identified so the buyer can decide whether to obtain it.
Stop or revise the requirement
No current option should advance, or a mandatory criterion excludes the available capability. No-match is a valid result.
What we do not do: publish live inventory, guarantee a match, certify a supplier, decide regulatory acceptance, or release a counterparty identity merely because a form was submitted.
Minimum useful brief
Start with the fields that can change the answer.
- Destination market and intended commercial use
- Product form and required cannabinoid range and basis
- Treatment or irradiation requirement
- Quantity, cadence, earliest need date and acceptable tolerance
- Required standards, tests, packaging and shelf life
- Known importer, processor, manufacturer or release pathway
- Target price, currency, unit and comparable delivery basis
- Required origin or origins that are excluded
- Decision-makers, purchasing stage and sample process
- Which criteria are mandatory and which can move
Approximate ranges are acceptable for the first screen. Full authority, document and route checks occur before any protected introduction. Do not submit patient information, identity documents, COAs or other confidential files through the public form.
How evidence is treated
Every material statement needs a state and a date.
“Verified” is too broad unless it says what was checked, by whom, when and for what scope.
Primary evidence
Registry status, document scope, dates, issuer, entity match and lot linkage are recorded where available.
Counterparty statements
Uncorroborated capacity, availability, pricing or route claims remain labelled as statements rather than converted into facts.
Unknowns and expiry
Unknown, pending, stale and expired evidence remain visible. An unknown cannot become a pass through optimistic wording.
Primary-source starting points
The route must be checked for the actual transaction.
These sources frame the diligence questions; they do not decide whether a particular lot, facility or shipment is acceptable.
- European Medicines Agency: GACP for starting materials of herbal origin — current guideline and revision history.
- European Commission: EudraLex Volume 4 — EU GMP guidance, including Annex 16.
- EudraGMDP — public records for manufacturing and import authorizations, GMP certificates and non-compliance statements.
- EUR-Lex: Directive 2001/83/EC, consolidated text — EU medicinal-product legal framework. Confirm applicability and current text with qualified advisers.
Continue researching
Useful next pages.
Start with demand
Bring one current buying requirement.
Provenance will return a credible-fit, missing-information or no-fit answer. No meeting is required to start.